EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessing the diagnostic value of oncological biomarkers for identifying primary malignancies in skeletal metastatic disease

Sanna Matilainen, Hanna Liikanen, Riitta Lassila, Minna K Laitinen

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.109688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Sanna Matilainen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics and Traumatology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. Electronic address: sanna.matila…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Bone Neoplasms, Neoplasms, Unknown Primary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Florida State University, Helsingin ja Uudenmaan Sairaanhoitopiiri.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Distinguishing primary malignancies from metastases is the primary objective of diagnosing bone tumors of unknown etiology. For metastatic bone disease, recognizing the primary disease is pivotal to plan appropriate treatment. Despite uncertainties, oncological biomarkers are commonly utilized for early diagnostics. METHODS: Laboratory biomarkers were retrospectively collected from electronic patient records of 193 individuals after oncologic examinations for unknown skeletal lesions during a 3-year period. Blood cell count, creatinine, PSA, Ca19-9, Ca15-3, Ca12-5, CEA, S-Prot, myeloma light chains and their ratio were assessed and analyzed statistically. RESULTS: An elevation in biomarker values was observed across all cancer types, indicating lack of specificity. Patients with increased CEA mostly had breast (29 %, NS) or lung (24 %, p=

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBone NeoplasmsNeoplasms, Unknown PrimaryHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overCA-19-9 AntigenCarcinoembryonic AntigenBreast NeoplasmsLung NeoplasmsSensitivity and Specificity

Stichwörter der Autor:innen

CA12-5CA15-3CA19-9CEAPSASkeletal metastasis

Substanzen

Biomarkers, TumorCA-19-9 AntigenCarcinoembryonic Antigen

Autor:innen und Institutionen

  • Department of Orthopedics and Traumatology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. Electronic address: sanna.matilainen@hus.fi.
  • Department of Orthopedics and Traumatology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and Research Program Unit of Systems Oncology, University of Helsinki, Helsinki, Finland.

Förderung

  • Florida State University
  • Helsingin ja Uudenmaan Sairaanhoitopiiri

Zitieren

APA

Matilainen, S., Liikanen, H., Lassila, R., & Laitinen, M. K. (2025). Assessing the diagnostic value of oncological biomarkers for identifying primary malignancies in skeletal metastatic disease. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.109688

Vancouver

Matilainen S, Liikanen H, Lassila R, Laitinen MK. Assessing the diagnostic value of oncological biomarkers for identifying primary malignancies in skeletal metastatic disease. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.109688

BibTeX
@article{Matilainen2025,
  author = {Matilainen, Sanna and Liikanen, Hanna and Lassila, Riitta and Laitinen, Minna K},
  title = {Assessing the diagnostic value of oncological biomarkers for identifying primary malignancies in skeletal metastatic disease},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.109688}
}
Kostenlos starten →